Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Breakthrough SARS-CoV-2 infections during periods of delta and omicron predominance, South Africa

2022; Elsevier BV; Volume: 400; Issue: 10348 Linguagem: Inglês

10.1016/s0140-6736(22)01190-4

ISSN

1474-547X

Autores

Ameena Goga, Linda‐Gail Bekker, Nigel Garrett, Tarylee Reddy, Nonhlanhla Yende‐Zuma, Lara Fairall, Harry Moultrie, Azwidihwi Takalani, Valentina Trivella, Mark Faesen, Veronique Bailey, Ishen Seocharan, Glenda Gray,

Tópico(s)

COVID-19 epidemiological studies

Resumo

The omicron variant of SARS-CoV-2 (B.1.1.529) was first detected in South Africa in November, 2021.1–3 Declared a variant of concern on Nov 26, 2021,4 omicron spread exponentially, replacing the delta variant (B.1.617.2) and driving rapid increases in COVID-19 cases.5,6 In-vitro experiments show that the omicron variant escapes antibody neutralisation in people who have previously been infected with or vaccinated against SARS-CoV-2.7,8 Epidemiological data suggest that vaccine effectiveness is reduced,9 and reinfection rates are higher for omicron than for the beta (B.1.351) and delta variants.

Referência(s)